Microbial production of value-added nutraceuticals

Jian Wang¹, Sanjay Guleria², Mattheos AG Koffas^{3,4,#} Yajun Yan^{5,#}

Addresses

¹ College of Engineering, University of Georgia, Athens, Georgia 30602, United States

² Division of Biochemistry, Sher-e-Kashmir University of Agricultural Sciences and Technology, Main Campus Chatha-180009, Jammu, India

³ Department of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies (CBIS), Rensselaer Polytechnic Institute, 110 8th Street, Troy, NY 12180, United States

⁴ Department of Biology, Center for Biotechnology and Interdisciplinary Studies (CBIS), Rensselaer Polytechnic Institute, 110 8th Street, Troy, NY 12180, United States

⁵ BioChemical Engineering Program, College of Engineering, University of Georgia, Athens, Georgia 30602, United States

[#] Co-corresponding authors

Koffas, Mattheos AG (koffam@rpi.edu)

Yan, Yajun (yajunyan@uga.edu)

Abstract

Nutraceuticals are important natural bioactive compounds that confer health-promoting and medical benefits to humans. Globally growing demands for value-added nutraceuticals for prevention and treatment of human diseases have rendered nutraceuticals a multi-billion dollar market. However, supply limitations and extraction difficulties from natural sources such as plants, animals or fungi, restrict the large-scale use of nutraceuticals. Metabolic engineering via microbial production platforms has been advanced as an eco-friendly alternative approach for production of value-added nutraceuticals from simple carbon sources. Microbial platforms like the most widely used *Escherichia coli* and *Saccharomyces cerevisiae* have been engineered as versatile cell factories for production of diverse and complex value-added chemicals such as phytochemicals, prebiotics, polysaccharides and poly amino acids. This review highlights the recent progresses in biological production of value-added nutraceuticals via metabolic engineering approaches.

Introduction

Nutraceutical, a hybrid term from “nutrition” and “pharmaceutical” coined by Stephen L. DeFelice in 1989, was defined as “any substance that is a food or a part of food and provides medical or health benefits, including the prevention and treatment of disease” [1]. Later on, the concept of nutraceutical was modified as “a product isolated or purified from foods that is generally sold in medicinal forms not usually associated with food” [2]. Nutraceuticals are now more specific to structurally and functionally diverse bioactive compounds that exert long-term medicinal or physiological benefits other than purely nutritional or direct pharmaceutical effects, which distinguishes them from functional foods and drugs. They can be derived from plants (e.g.

42 phytochemicals, vitamins), from animals (e.g. polysaccharides), from microorganisms (e.g. poly
43 amino acids) and from marine sources (e.g. glucosamine and chitosan). Nutraceuticals are widely
44 used for their health-promoting or disease-preventing properties especially in preventing
45 aging-associated diseases including oxidative stress, depression, inflammation, arthritis,
46 osteoporosis, gastrointestinal diseases, cardiovascular diseases, diabetes and cancer [3]. The rising
47 demands and interests in maintaining human wellness through diet have greatly promoted the
48 growth of the nutraceutical market. According to Global Information Inc.' recent report, the global
49 nutraceutical market was estimated to exceed \$171.8 billion in 2014 and reach \$241.1 billion by
50 2019, while the US market alone was about \$75.9 billion [3].

51 However, the expanding nutraceutical market can hardly be fulfilled by the productivity of
52 conventional nutraceutical industries. Direct extraction strategies are limited by the availability
53 and cost of raw materials, the quality control of supplies, and the low content and purity of
54 nutraceuticals. Although chemical synthesis is an alternative approach, it is limited to producing
55 simple biochemicals and is infeasible for complex biochemicals especially those that are
56 chemically unfavorable [4]. To address these issues, microbial-based metabolic engineering is an
57 appealing approach and has achieved great progress on production of value-added nutraceuticals
58 in very recent years. The rapid elucidation of biosynthetic pathways for natural products and the
59 genetic amenability of microorganisms have enabled the development of microbial hosts for
60 production of various nutraceuticals. By further genetic manipulation of host cells and
61 optimization of the culture conditions or fermentation processes, metabolic engineering makes it
62 possible to scale up the production of nutraceuticals from simple carbon sources. As a matter of
63 fact, certain commercial *E. coli* strains and food-grade *S. cerevisiae* have been industrially used as
64 cell factories to produce natural products Generally Recognized As Safe (GRAS). This review
65 covers recent advances in nutraceutical production via microbial-based metabolic engineering,
66 including the well-studied phytochemicals, as well as prebiotics, polysaccharides and poly amino
67 acids.

68 69 **Phytochemicals**

70 Phytochemicals are a broad spectrum of plant-derived bioactive secondary metabolites that are
71 commonly found in fruits, vegetables, beans and grains. They are involved in plant defenses
72 against biotic or abiotic stresses, and also exhibit health-protecting or disease-preventing effects
73 on humans [3]. Phytochemicals is a vast and very important repertoire for nutraceuticals, which
74 include polyphenolic compounds (flavonoids, isoflavonoids, stilbenoids and curcuminoids),
75 alkaloids, terpenoids (monoterpenes, diterpenes, tetraterpenes, polyterpenes, steroid saponins,
76 lycopene and carotenoids) and their derived compounds.

77 ***Polyphenolic compounds***

78 Amongst the phytochemicals, polyphenolic compounds have been used for decades as effective
79 antioxidants and food ingredients in the nutraceutical industry. Polyphenolic scaffolds such as
80 flavonoids and stilbenoids are derived from the phenylpropanoic pathway that extends from
81 aromatic amino acids L-phenylalanine and L-tyrosine (Figure 1) [5]. L-phenylalanine and
82 L-tyrosine are converted to pivotal intermediates cinnamic acid and *p*-coumaric acid via
83 phenylalanine ammonia lyase (PAL) and tyrosine ammonia lyase (TAL), which are further
84 converted to cinnamoyl-CoA and *p*-coumaroyl-CoA by 4-coumaroyl-CoA ligase (4CL),

85 respectively. Then, three moles of malonyl-CoA condense with cinnamoyl-CoA or
86 *p*-coumaroyl-CoA to construct the backbone flavanones, stilbenes or curcuminoids by type III
87 polyketide synthases, such as chalcone synthase (CHS), curcuminoid synthase (CUS) or stilbene
88 synthase (STS) [6]. With the action of tailoring enzymes such as hydroxylases,
89 *O*-methyltransferases, glucosyltransferase, lipases and prenyltransferase, diverse polyphenolic
90 compounds are generated [7].

91 *E. coli* and *S. cerevisiae* have generally been developed as platform organisms for *de novo* or
92 semi-*de novo* production of almost all kinds of polyphenolic compounds (Table 1). Some of the
93 biggest advantages of *E. coli* include its fast growth and ease of genetic manipulation; for *S.*
94 *cerevisiae* its Generally Regarded As Safe (GRAS) status and its ability to functionally express
95 plant metabolic enzymes. In all cases, in order to achieve polyphenolic compound production in
96 microbes, plant-originated enzymes are firstly overexpressed via either codon optimization or
97 construction of enzyme chimeras that facilitate bacterial expression [8]. The first strategy is
98 feeding precursors to the heterologous hosts to produce corresponding polyphenolic compounds.
99 For example, supplementation with phenylalanine to *E. coli* expressing heterologous pathways
100 produced chrysin (9.4 mg/L) or galangin (1.1 mg/L) while supplementation with tyrosine led to
101 the production of apigenin (13 mg/L) or kaempferol (15.1 mg/L) (Table 1) [9]. This feeding
102 approach is widely used when precursors are low or cannot be biosynthesized in microbes.
103 Flavonoid glucosides like luteolin 4'-*O*- and 7'-*O*-glucosides were produced by feeding luteolin to
104 *E. coli* expressing glycosyltransferases UGT71G1 [10]. By expressing glycosyltransferases with
105 different substrate specificities, quercetin 3-*O*-glucoside, quercetin-3-*O*-glucuronide, quercetin
106 3-*O*-galactoside and quercetin-3-*O*-rhamnoside were respectively produced (Table 1) [10-12]. The
107 second approach is *de novo* biosynthesis of phenolic compounds from simple carbon sources like
108 glucose and glycerol, which is more appealing for industrial applications. *E. coli* hosts can be
109 easily metabolically engineered to overproduce L-phenylalanine and L-tyrosine from simple
110 carbon sources. The intracellular concentration of malonyl-CoA, the extender unit for
111 polyphenolic backbones, can be greatly enhanced in *E. coli* by overexpressing acetyl-CoA
112 carboxylase (ACC) or genome-scale metabolic optimization or by repressing malonyl-CoA
113 consumption pathways using antisense RNA [13,14]. *E. coli* has been successfully utilized for *de*
114 *nov*o biosynthesis of certain polyphenolic compounds such as pinocembrin, pinosylvin,
115 sakuranetin and ponciretin [15-17]. Furthermore, substrate promiscuity of authentic or engineered
116 enzymes has provided with new possibilities to produce novel or non-natural polyphenolic
117 compounds [18,19].

118 **Alkaloids**

119 Alkaloids are amino acid-derived nitrogenous compounds that have important therapeutic
120 values, including anticancer and antimalarial effects [5]. For a long time, production of alkaloids
121 was limited to plants because of their complex structure and long biosynthetic pathways. The three
122 most well-known alkaloids are benzylisoquinoline alkaloids (BIAs) derived from tyrosine,
123 monoterpene indole alkaloids (MIAs) derived from tryptophan and glucosinolates. In recent years,
124 elucidation of many BIA biosynthetic pathways enabled the reconstruction of BIA pathways in
125 both *E. coli* and *S. cerevisiae* [20-22]. (*S*)-reticuline, a branch-point intermediate for BIA, was
126 biosynthesized from simple carbon sources with titer of 46.0 mg/L [20]. Bacteria consortia of *E.*
127 *coli* producing (*S*)-reticuline and *S. cerevisiae* producing either monooxygenase CYP80G2 or the
128 berberine bridge enzyme (BBE) yielded 7.2 mg/L magnoflorine and 8.3 mg/L scoulerine,

respectively (Figure1) [23]. *S. cerevisiae* was also enabled to produce (*R,S*)-reticuline and was further engineered to generate scoulerine, tetrahydrocolumbamine and tetrahydroberberine from (*S*)-reticuline and salutaridine from (*R*)-reticuline [24]. However, metabolic engineering of MIA alkaloids in microbes is limited. Recently, *de novo* production of the MIA alkaloid strictosidine has been achieved in yeast by introducing 21 new genes and deleting 3 genes in the yeast genome (Table 1) [25]. Glucosinolates are sulfur-rich, amino acid-derived natural compounds. Tryptophan-derived indolylglucosinolate (IG) has recently been produced in *S. cerevisiae* by inserting eight plant genes into the genome, which represents a rare example of glucosinolate production in microbes (Figure 1) [26]. Although plant platforms are more suitable for scalable alkaloid production, metabolic engineering in microbes has shown potential capability for cost-efficient production of these plant-derived compounds [7,25].

Terpenoids

Terpenoids are present in green foods, soy plants and cereals, and serve as the largest class of phytonutrients with anti-inflammatory, anti-infectious and anti-cancer properties [3,7]. Terpenoids are isopentenyl pyrophosphate (IPP) or dimethylallyl pyrophosphate (DMAPP) derived compounds of diverse carbon skeletons, including monoterpenes (C₁₀, e.g. menthol), sesquiterpenes (C₁₅, e.g. artemisinin), diterpenes (C₂₀, e.g. paclitaxel), triterpens (C₃₀, e.g. steroids), tetraterpenes (C₄₀, carotenoids) and polyterpenes [5]. Microbial production of terpenoids such as taxadiene (intermediate of anticancer drug paclitaxel) and artemisinic acid (precursor of antimalarial drug artemisinin) exemplified the advances and successes of metabolic engineering for production of value-added terpenoid pharmaceuticals. In nutraceutical industries, tetraterpene carotenoids such as β -carotene, lutein, lycopene, α -carotene and astaxanthin serve as natural food colorants and feed supplements [5]. Combinatorial carotenoid biosynthesis in heterologous non-carotenogenic hosts like *E. coli* and *S. cerevisiae* has been achieved for decades. Since then, metabolic engineering efforts have mainly focused on large-scale production of carotenoids. Strain optimization via systematic and combinatorial gene knockouts significantly increased lycopene production in *E. coli* [6]. Engineering central metabolic modules of *E. coli* to increase ATP and NADPH supplies improved β -carotene production to 2.1 g/L β -carotene with a yield of 60 mg/g DCW [27]. Lycopene derived zeaxanthin was biosynthesized and its production improved to 43.46 mg/L via protein fusion approaches for coordinating expression of lycopene β -cyclase gene *crtY* and β -carotene 3-hydroxylase gene *crtZ* [28]. A plasmid-free *E. coli* strain with the xanthophyll biosynthetic genes chromosomally integrated produced astaxanthin with a yield of 1.4 mg/g DCW [29]. Besides conventional carotenoids, discovery and production of new carotenoids with health-promoting benefits have also increased the pool of available carotenoids. Novel carotenoids such as 4-ketozeinoxanthin and the rare C₅₀ carotenoids sarcinaxanthin, decaprenoxanthin and sarprenoxanthin have been produced in lycopene-producing *E. coli* hosts [30,31]. Recently, a non-natural purple carotenoid C₅₀-astaxanthin was produced in *E. coli* using mutants of the first two pathway enzymes, farnesyl diphosphate synthase (FDS) and carotenoid synthase (CrtM), with shifted size-range substrate selectivities to enhance production of C₅₀ backbone while suppress non-target compounds [32].

Prebiotics

A prebiotic is defined as “a nonviable food component that confers a health benefit on the host associated with modulation of the microbiota” by The Food and Agriculture Organization of the

United Nations (FAO) [33]. Prebiotics are non-digestible saccharide polymers that contain 3–10 monomeric sugar units (Figure 2). The beneficial effects of prebiotics on humans lie in their modulation on diversity and metabolic activity of the gut microbiota, which may consequently have significant impact on the host immune system. Thus, prebiotics could be used to treat inflammatory diseases by boosting probiotics like *Bifidobacteria* or *Lactobacillus* species within the gut microbiota [34]. Representative prebiotics include inulin, fructo-oligosaccharides (FOS) and galacto-oligosaccharides (GOS). Inulin and inulin-type fructans, also known as soluble dietary fibres, could be produced by probiotic *Lactobacillus gasseri* strains [35]. GOS are lactose-derived galactose polymers with shorter polymer chains. GOS could be produced by *Kluyveromyces lactis* with a titer of 177 g/L from 400 g/L lactose [36]. Expression of codon-optimized β -galactosidase from the hyperthermophile *Sulfolobus solfataricus* in *Lactococcus lactis* efficiently converted lactose to GOS [37]. 2'-fucosyllactose (2'-FL) is one of the most abundant oligosaccharides in human milk and has been approved as nutritional additive in term infant and toddler formulas. By increasing the availability GDP-L-fucose and overexpression of fucosyltransferase, 2'-FL could be largely produced from lactose and glycerol in *E. coli* [38,39].

Polysaccharides

Polysaccharides are sugar polymers of versatile structures that can be largely produced by several bacteria, yeast and fungi or extracted from plant and animal tissues (Figure 2). Microbial polysaccharides have been recognized as a source for nutraceuticals owing to their health-beneficial properties. Bacterial polysaccharides such as xanthan, gellan, dextrans and alginate can be commercialized via microbial production and purification [40]. Exopolysaccharides (EPS) are preferentially produced via metabolic engineering of *Lactococcus* and *Streptococcus* for their wide use in dairy products. Especially, bioactive fungal polysaccharides have demonstrated extensive immunostimulating, antitumor, antimicrobial, antioxidant, hypocholesterolaemic and hypoglycaemic benefits, thus indicating great potential in both nutraceutical and pharmaceutical applications [41]. Potential antitumor and antiviral polysaccharide scleroglucan is an extracellular glucan excreted by mycelia of *Sclerotium rolfsii*, whose yields could be enhanced via addition of L-lysine and uridine mono-phosphate (UMP) [41]. Instead of extraction from animal tissues, several animal polysaccharides like hyaluronic acid (HA), chondroitin and heparosan have also been produced by microbial hosts. Microbial production of hyaluronic acid has been achieved in various hosts including *E. coli*, *Lactococcus lactis* and *Streptomyces albulus* [42-44]. Medicinally important polysaccharides such as heparosan and chondroitin can be produced by engineered *E. coli* reaching a relatively high titer of 1.88 g/L and 2.4 g/L, respectively (Table 1) [45,46].

Poly amino acids

Poly amino acids are synthesized in microorganisms from one or two type of amino acids by ribosome-independent enzymatic processes that distinguish them from protein synthesis. Three kinds of poly amino acids, namely poly- γ -glutamic acid (γ -PGA), poly- ϵ -L-lysine (ϵ -PL) and multi-L-arginyl-poly(L-aspartic acid) (cyanophycin), are present in nature (Figure 2). γ -PGA is a water-soluble and biodegradable polymer that can be used as a degradable biomaterial such as drug carriers or hydrogels. γ -PGA can be largely produced (20-50 g/L) by *Bacillus* species when

feeding L-glutamic acid. In order to achieve γ -PGA production from glucose, optimization of co-cultivation of *Corynebacterium glutamicum* and *Bacillus subtilis* could maximally produce 32.8 g/L γ -PGA [47]. Cyanophycin was produced from equimolar amounts of arginine and aspartic acid by cyanobacteria and some other chemotrophic bacteria (e. g. *Acinetobacter calcoaceticus*), which can be used as a precursor of dipeptides for nutritional and therapeutic applications. Overexpression of cyanophycin synthetase *cphA* from *Synechocystis* sp. PCC 6803 in *E. coli* achieved cyanophycin production with productivity of 120 mg/g CDW [48]. ϵ -PL is a microbial-derived homo-poly amino acid that is synthesized by polymerization of lysine via ϵ -PL synthetase (PLS). ϵ -PL possesses antibacterial and anticancer activities and has been approved as food preservative or dietary agent in Japan and United States [49]. ϵ -PL was produced by *Streptomyces* species such as *Streptomyces albulus*. Production of ϵ -PL in *Streptomyces* sp. M-Z18 could reach 35.14 g/L when using glucose and glycerol as carbon sources [64].

Conclusions

The last few decades have witnessed the remarkable progresses of nutraceuticals production via metabolic engineering of microbial-based platforms, which is in response to the great demands for value-added nutraceuticals to fortify humans against diseases. Metabolic engineering in microbes made possible not only the laboratory-scale preparation but also industrial-scale production of complex natural products such as carotenoids from simple carbon sources. Especially, with the elucidation of biosynthetic pathways and development of synthetic biology strategies, novel or more complicated value-added compounds could be produced in microbes in a naturally developed manner. The amenability of genetic manipulation and tolerance of heterologous enzymes enabled microbes to produce diverse nutraceuticals via harnessing their native metabolic networks. One of the major limitations of microbial platform is the efficiency of plant or animal-derived enzymes that limit the productivity of the target compounds. While other non-microbial production platforms such as algae and plant-derived cell cultures have also been developed to produce natural or non-natural value-added nutraceuticals, there is little doubt that continuing advances in metabolic engineering and synthetic biology will allow the production of virtually any nutraceutical through a microbial host.

ACKNOWLEDGMENTS

Mattheos Koffas acknowledges partial financial support from NSF grant number MCB-1448657.

Table 1. Biological production of nutraceuticals via metabolic engineering in different hosts

Nutraceuticals	Heterologous hosts	Fed precursors	Titers (mg/L)	References
Polyphenolic compounds				
Apigenin (Flavone)	<i>E. coli</i>	Tyrosine	13	[9]
Chrysin (Flavone)	<i>E. coli</i>	Phenylalanine	9.4	[9]
Pinocembrin (Flavanone)	<i>E. coli</i>	Glucose	40.2	[15]
Eriodictyol (Flavanone)	<i>E. coli</i>	Tyrosine	107	[51]
Naringenin (Flavanone)	<i>S. cerevisiae</i>	Glucose	108.9	[52]
Catechin (Flavanonol)	<i>E. coli</i>	Eriodictyol	910.9	[53]
Genistein (Isoflavonone)	<i>E. coli-S. cerevisiae</i>	Tyrosine	6	[54]
Resveratrol (Stilbenoid)	<i>E. coli</i>	Tyrosine	35.02	[55]

Pinosylvin (Stilbenoid)	<i>E. coli</i>	Glucose	70	[16]
Curcumin (Curcuminoid)	<i>E. coli</i>	Tyrosine	0.6	[56]
Caffeic acid	<i>E. coli</i>	Glucose and glycerol	766.68	[57]
Flavonoid derivatives				
Sakuranetin	<i>E. coli</i>	Glucose	42.5	[17]
Ponciretin	<i>E. coli</i>	Glucose	40.1	[17]
7-O-Methyl aromadendrin	<i>E. coli</i>	p-coumaric acid	2.7	[58]
Luteolin 4-O-glucosides	<i>E. coli</i>	Luteolin	10.86	[10]
Luteolin 7-O-glucosides	<i>E. coli</i>	Luteolin	6.52	[10]
Luteolin-7-O-glucuronide	<i>E. coli</i>	Luteolin	300	[11]
Kaempferol 3-O-glucoside	<i>E. coli</i>	Naringenin	109.3	[10]
Kaempferol-3-O-rhamnoside	<i>E. coli</i>	Kaempferol	150	[12]
Quercetin 3-O-glucoside	<i>E. coli</i>	Quercetin	11.54	[10]
Quercetin-3-O-glucuronide	<i>E. coli</i>	Quercetin	687	[11]
Quercetin-3-O-rhamnoside	<i>E. coli</i>	Quercetin	200	[12]
Anthocyanin	<i>E. coli</i>	Catechin	110	[59]
Genistein glucosides	<i>E. coli</i>	Genistein	37.29	[60]
Genistin	<i>S. cerevisiae</i>	Genistein	-	[61]
Daidzin	<i>S. cerevisiae</i>	Daidzein	-	[8]
3-Hydroxydaidzein	<i>E. coli</i>	Daidzein	75	[61]
Alkaloids				
(S)-reticuline (Benzylisoquinoline alkaloid)	<i>E. coli</i>	Glycerol	46	[20]
Strictosidine (Monoterpene indole alkaloid)	<i>S. cerevisiae</i>	Glucose	0.53	[25]
Indolylglucosinolate (Glucosinolate)	<i>S. cerevisiae</i>	Glucose	1.07	[26]
Terpenoids				
Lycopene	<i>E. coli</i>	Glucose	18 mg/g	[62]
β-carotene	<i>E. coli</i>	Glucose	2100	[27]
Zeaxanthin	<i>E. coli</i>	Glucose	43.46	[28]
Astaxanthin	<i>E. coli</i>	Glucose	1.4 mg/g	[29]
Prebiotics				
2-Fucosyllactose	<i>E. coli</i>	Lactose and glycerol	20280	[39]
Galactooligosaccharides	<i>Lactococcus lactis</i>	Lactose	197000	[37]
Polysaccharides				
Heparosan	<i>E. coli</i>	Glycerol	1880	[46]
Hyaluronan	<i>Streptomyces albulus</i>	Sucrose	6200	[42]
Scleroglucan	<i>Sclerotium rolfii</i>	Uridine	22320	[63]
		Mono-phosphate		
Chondroitin	<i>E. coli</i>	Glucose	2400	[45]
Poly amino acids				

Poly-ε-L-lysine	<i>Streptomyces</i> <i>sp.M-Z18</i>	Glucose and glycerol	35140	[64]
Poly-γ-glutamic acid	<i>Bacillus subtilis</i> BL53	L-glutamic acid and glycerol	17000	[65]
Cyanophycin	<i>E. coli</i>	Yeast extract	120 mg/g	[48]

Figure 1. Examples of microbial-based production of phytochemicals from aromatic amino acids. Arrows represent the metabolic flux from primary shikimate pathway to target phytochemicals. Polyphenolic compounds are derived from phenylalanine or tyrosine, benzylisoquinoline alkaloids (BIA) are derived from tyrosine, monoterpene indole alkaloids (MIA) and indolylglucosinolate (IG) are derived from tryptophan.

Figure 2. Representatives of microbial-produced prebiotics, polysaccharides and poly amino acids.

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

. of special interest

.. of outstanding interest

- DeFelice SL: **The nutraceutical revolution: its impact on food industry R&D.** *Trends Food Sci Technol* 1995, **6**:59-61.
- Pandey M, Verma RK, Saraf SA: **Nutraceuticals: new era of medicine and health.** *Asian J Pharm Clin Res* 2010, **3**:11-15.
- Jain N, Ramawat KG: **Nutraceuticals and antioxidants in prevention of diseases.** *Natural Products*. Springer; 2013:2559-2580.
- De Luca V, Salim V, Atsumi SM, Yu F: **Mining the biodiversity of plants: a revolution in the making.** *Science* 2012, **336**:1658-1661.
- Marienhagen J, Bott M: **Metabolic engineering of microorganisms for the synthesis of plant natural products.** *J Biotechnol* 2013, **163**:166-178.
- Lin Y, Jain R, Yan Y: **Microbial production of antioxidant food ingredients via metabolic engineering.** *Curr Opin Biotechnol* 2014, **26**:71-78.
- Mora-Pale M, Sanchez-Rodriguez SP, Linhardt RJ, Dordick JS, Koffas MA: **Metabolic engineering and *in vitro* biosynthesis of phytochemicals and non-natural analogues.** *Plant Sci* 2013, **210**:10-24.
- Leonard E, Koffas MA: **Engineering of artificial plant cytochrome P450 enzymes for synthesis of isoflavones by *Escherichia coli*.** *Appl Environ Microbiol* 2007, **73**:7246-7251.
- Miyahisa I, Funa N, Ohnishi Y, Martens S, Moriguchi T, Horinouchi S: **Combinatorial biosynthesis of flavones and flavonols in *Escherichia coli*.** *Appl Microbiol Biotechnol* 2006,

- 289 71:53-58.
- 290 10. He X-Z, Li W-S, Blount JW, Dixon RA: **Regioselective synthesis of plant (iso) flavone**
 291 **glycosides in *Escherichia coli***. *Appl Microbiol Biotechnol* 2008, **80**:253-260.
- 292 11. Kim SY, Lee HR, Park K-s, Kim B-G, Ahn J-H: **Metabolic engineering of *Escherichia coli***
 293 **for the biosynthesis of flavonoid-O-glucuronides and flavonoid-O-galactoside**. *Appl*
 294 *Microbiol Biotechnol* 2015, **99**:2233-2242.
- 295 12. Kim B-G, Kim HJ, Ahn J-H: **Production of bioactive flavonol rhamnosides by expression**
 296 **of plant genes in *Escherichia coli***. *J Agric Food Chem* 2012, **60**:11143-11148.
- 297 13. Xu P, Ranganathan S, Fowler ZL, Maranas CD, Koffas MA: **Genome-scale metabolic**
 298 **network modeling results in minimal interventions that cooperatively force carbon flux**
 299 **towards malonyl-CoA**. *Metab Eng* 2011, **13**:578-587.
- 300 14. Yang Y, Lin Y, Li L, Linhardt RJ, Yan Y: **Regulating malonyl-CoA metabolism via**
 301 **synthetic antisense RNAs for enhanced biosynthesis of natural products**. *Metab Eng* 2015,
 302 **29**:217-226.
- 303 The authors demonstrated the effectiveness of asRNA as a powerful tool to achieve malonyl-CoA
 304 enrichment via down-regulating fatty acid biosynthesis in *Escherichia coli*, which led to improved
 305 production of natural products 4-hydroxycoumarin, resveratrol and naringenin.
- 306 15. Wu J, Du G, Zhou J, Chen J: **Metabolic engineering of *Escherichia coli* for**
 307 **(2S)-pinocembrin production from glucose by a modular metabolic strategy**. *Metab Eng*
 308 2013, **16**:48-55.
- 309 16. van Summeren-Wesenhagen PV, Marienhagen J: **Metabolic engineering of *Escherichia coli***
 310 **for the synthesis of the plant polyphenol pinosylvin**. *Appl Environ Microbiol* 2015,
 311 **81**:840-849.
- 312 17. Kim M-J, Kim B-G, Ahn J-H: **Biosynthesis of bioactive O-methylated flavonoids in**
 313 ***Escherichia coli***. *Appl Microbiol Biotechnol* 2013, **97**:7195-7204.
- 314 18. Bhan BFC, R. J. Linhardt, M.A.G. Koffas: **Expanding the chemical space of polyketides**
 315 **through structure-guided mutagenesis of *Vitis vinifera* stilbene synthase**. *Biochimie* 2015.
- 316 Demonstration of the application of enzyme promiscuity and the feasibility of rational enzyme
 317 engineering of stilbene synthase to produce multiple non-natural polyketides.
- 318 19. Bhan N, Li L, Cai C, Xu P, Linhardt RJ, Koffas MA: **Enzymatic formation of a resorcylic**
 319 **acid by creating a structure-guided single-point mutation in stilbene synthase**. *Protein Sci*
 320 2015, **24**:167-173.
- 321 20. Nakagawa A, Minami H, Kim J-S, Koyanagi T, Katayama T, Sato F, Kumagai H: **A bacterial**
 322 **platform for fermentative production of plant alkaloids**. *Nat Commun* 2011, **2**:326.
- 323 The authors established a bacterial platform for plant alkaloid (S)-reticuline production (46 mg/L) from
 324 simple carbon source glycerol, suggesting its feasibility as a fermentation platform for low-cost
 325 production of diverse plant alkaloids.
- 326 21. Fossati E, Ekins A, Narcross L, Zhu Y, Falgueyret J-P, Beaudoin GA, Facchini PJ, Martin VJ:
 327 **Reconstitution of a 10-gene pathway for synthesis of the plant alkaloid**
 328 **dihydrosanguinarine in *Saccharomyces cerevisiae***. *Nat Commun* 2014, **5**.
- 329 22. Nakagawa A, Matsuzaki C, Matsumura E, Koyanagi T, Katayama T, Yamamoto K, Sato F,
 330 Kumagai H, Minami H: **(R, S)-Tetrahydropapaveroline production by stepwise**
 331 **fermentation using engineered *Escherichia coli***. *Sci Rep* 2014, **4**.
- 332 23. Minami H, Kim J-S, Ikezawa N, Takemura T, Katayama T, Kumagai H, Sato F: **Microbial**

333 **production of plant benzyloquinoline alkaloids.** *Proc Natl Acad Sci U S A* 2008,
334 **105:7393-7398.**

335 24. Hawkins KM, Smolke CD: **Production of benzyloquinoline alkaloids in *Saccharomyces***
336 ***cerevisiae*.** *Nat Chem Biol* 2008, **4:564-573.**

337 25. Brown S, Clastre M, Courdavault V, O'Connor SE: **De novo production of the**
338 **plant-derived alkaloid strictosidine in yeast.** *Proc Natl Acad Sci U S A* 2015,
339 **112:3205-3210.**

340 First report of *de novo* production of a plant-derived monoterpene indole alkaloid strictosidine (0.5
341 mg/L) in yeast by introducing a 21-gene pathway and deleting 3 genes of yeast.

342 26. Mikkelsen MD, Buron LD, Salomonsen B, Olsen CE, Hansen BG, Mortensen UH, Halkier
343 BA: **Microbial production of indolylglucosinolate through engineering of a multi-gene**
344 **pathway in a versatile yeast expression platform.** *Metab Eng* 2012, **14:104-111.**

345 First production of plant-derived glucosinolates in a stable and robust microbial host by integrating
346 multi-gene pathways (up to 22 genes) into the yeast genome.

347 27. Zhao J, Li Q, Sun T, Zhu X, Xu H, Tang J, Zhang X, Ma Y: **Engineering central metabolic**
348 **modules of *Escherichia coli* for improving β -carotene production.** *Metab Eng* 2013,
349 **17:42-50.**

350 28. Li X-R, Tian G-Q, Shen H-J, Liu J-Z: **Metabolic engineering of *Escherichia coli* to produce**
351 **zeaxanthin.** *J Ind Microbiol Biotechnol* 2015, **42:627-636.**

352 29. Lemuth K, Steuer K, Albermann C: **Engineering of a plasmid-free *Escherichia coli* strain**
353 **for improved *in vivo* biosynthesis of astaxanthin.** *Microb Cell Fact* 2011, **10:29.**

354 30. Netzer R, Stafsnes MH, Andreassen T, Goksøyr A, Bruheim P, Brautaset T: **Biosynthetic**
355 **pathway for γ -cyclic sarcinaxanthin in *Micrococcus luteus*: Heterologous expression and**
356 **evidence for diverse and multiple catalytic functions of C50 carotenoid cyclases.** *J*
357 *Bacteriol* 2010, **192:5688-5699.**

358 31. Maoka T, Takemura M, Tokuda H, Suzuki N, Misawa N: **4-Ketozeinoxanthin, a novel**
359 **carotenoid produced in *Escherichia coli* through metabolic engineering using**
360 **carotenogenic genes of bacterium and liverwort.** *Tetrahedron Lett* 2014, **55:6708-6710.**

361 32. Furubayashi M, Ikezumi M, Takaichi S, Maoka T, Hemmi H, Ogawa T, Saito K, Tobias AV,
362 Umeno D: **A highly selective biosynthetic pathway to non-natural C50 carotenoids**
363 **assembled from moderately selective enzymes.** *Nat Commun* 2015, **6.**

364 The authors established a pathway that selectively produced non-natural carotenoid C₅₀-astaxanthin by
365 screening variants of the first two enzymes with shifted substrate specificity and combining them to
366 channel precursors to C₅₀ backbones.

367 33. Pineiro M, Asp N-G, Reid G, Macfarlane S, Morelli L, Brunser O, Tuohy K: **FAO Technical**
368 **meeting on prebiotics.** *J Clin Gastroenterol* 2008, **42:S156-S159.**

369 34. Lin C-S, Chang C-J, Lu C-C, Martel J, Ojcius DM, Ko Y-F, Young JD, Lai H-C: **Impact of**
370 **the gut microbiota, prebiotics, and probiotics on human health and disease.** *Biomed J*
371 2014, **37:259.**

372 35. Anwar MA, Kralj S, Piqué AV, Leemhuis H, van der Maarel MJ, Dijkhuizen L: **Inulin and**
373 **levan synthesis by probiotic *Lactobacillus gasseri* strains: characterization of three novel**
374 **fructansucrase enzymes and their fructan products.** *Microbiology* 2010, **156:1264-1274.**

375 36. Rodriguez-Colinas B, de Abreu MA, Fernandez-Arrojo L, de Beer R, Poveda A,
376 Jimenez-Barbero J, Haltrich D, Ballesteros Olmo AO, Fernandez-Lobato M, Plou FJ:

377 **Production of galacto-oligosaccharides by the β -galactosidase from *Kluyveromyces lactis*:**
378 **Comparative analysis of permeabilized cells versus soluble enzyme. *J Agric Food Chem***
379 2011, **59**:10477-10484.

380 37. Yu L, O'Sullivan D: **Production of galactooligosaccharides using a hyperthermophilic**
381 **β -galactosidase in permeabilized whole cells of *Lactococcus lactis*. *J Dairy Sci* 2014,**
382 **97**:694-703.

383 38. Lee W-H, Pathanibul P, Quarterman J, Jo J-H, Han NS, Miller MJ, Jin Y-S, Seo J-H: **Whole**
384 **cell biosynthesis of a functional oligosaccharide, 2'-fucosyllactose, using engineered**
385 ***Escherichia coli*. *Microb Cell Fact* 2012, 11:48.**

386 39. Baumgärtner F, Seitz L, Sprenger GA, Albermann C: **Construction of *Escherichia coli***
387 **strains with chromosomally integrated expression cassettes for the synthesis of**
388 **2'-fucosyllactose. *Microb Cell Fact* 2013, 12:40.**

389 First establishment of selection marker-free *E. coli* strain that produces 2'-FL with a final titer of 20.28
390 g/L in fed-batch fermentation from lactose and glycerol.

391 40. Giavasis I: **Production of microbial polysaccharides for use in food. *Microbial Production***
392 ***of Food Ingredients, Enzymes and Nutraceuticals*. Woodhead Publishing; 2013:413-468.**

393 41. Giavasis I: **Bioactive fungal polysaccharides as potential functional ingredients in food**
394 **and nutraceuticals. *Curr Opin Biotechnol* 2014, 26:162-173.**

395 42. Yoshimura T, Shibata N, Hamano Y, Yamanaka K: **Heterologous production of hyaluronic**
396 **acid in an ϵ -poly-L-lysine producer, *Streptomyces albulus*. *Appl Environ Microbiol* 2015,**
397 **81**:3631-3640.

398 43. Yu H, Stephanopoulos G: **Metabolic engineering of *Escherichia coli* for biosynthesis of**
399 **hyaluronic acid. *Metab Eng* 2008, 10:24-32.**

400 44. Sheng J, Ling P, Wang F: **Constructing a recombinant hyaluronic acid biosynthesis**
401 **operon and producing food-grade hyaluronic acid in *Lactococcus lactis*. *J Ind Microbiol***
402 ***Biotechnol* 2015, 42:197-206.**

403 45. He W, Fu L, Li G, Jones JA, Linhardt RJ, Koffas M: **Production of chondroitin in**
404 **metabolically engineered *E. coli*. *Metab Eng* 2015, 27:92-100.**

405 First successful demonstration of high-titer production of chondroitin (2.4 g/L) in a non-pathogenic *E.*
406 *coli* strain that opens the gates for production of chondroitin-derived polysaccharides with nutraceutical
407 or pharmaceutical applications.

408 46. Zhang C, Liu L, Teng L, Chen J, Liu J, Li J, Du G, Chen J: **Metabolic engineering of**
409 ***Escherichia coli* BL21 for biosynthesis of heparosan, a bioengineered heparin precursor.**
410 ***Metab Eng* 2012, 14:521-527.**

411 47. Shi F, Xu Z, Cen P: **Microbial production of natural poly amino acid. *Sci China Ser B***
412 **2007, 50:291-303.**

413 48. Tseng WC, Fang TY, Cho CY, Chen PS, Tsai CS: **Assessments of growth conditions on the**
414 **production of cyanophycin by recombinant *Escherichia coli* strains expressing**
415 **cyanophycin synthetase gene. *Biotechnol Progr* 2012, 28:358-363.**

416 49. El-Sersy NA, Abdelwahab AE, Abouelkhiir SS, Abou-Zeid DM, Sabry SA: **Antibacterial**
417 **and anticancer activity of ϵ -poly-L-lysine (ϵ -PL) produced by a marine *Bacillus subtilis* sp.**
418 ***J Basic Microbiol* 2012, 52:513-522.**

419 50. Kroll J, Klintner S, Steinbüchel A: **A novel plasmid addiction system for large-scale**
420 **production of cyanophycin in *Escherichia coli* using mineral salts medium. *Appl***

421 *Microbiol Biotechnol* 2011, **89**:593-604.

422 51. Zhu S, Wu J, Du G, Zhou J, Chen J: **Efficient synthesis of eriodictyol from L-tyrosine in**

423 ***Escherichia coli*. *Appl Environ Microbiol* 2014, **80**:3072-3080.**

424 52. Koopman F, Beekwilder J, Crimi B, van Houwelingen A, Hall RD, Bosch D, van Maris A,

425 Pronk JT, Daran J-M: ***De novo* production of the flavonoid naringenin in engineered**

426 ***Saccharomyces cerevisiae*. *Microb Cell Fact* 2012, **11**:155.**

427 First report of *de novo* production of naringenin in yeast from glucose via optimization of the product

428 pathway, improvement of precursor supply and reduction of byproducts.

429 53. Zhao S, Jones JA, Lachance DM, Bhan N, Khalidi O, Venkataraman S, Wang Z, Koffas MA:

430 **Improvement of catechin production in *Escherichia coli* through combinatorial**

431 **metabolic engineering. *Metab Eng* 2015, **28**:43-53.**

432 54. Katsuyama Y, Miyahisa I, Funa N, Horinouchi S: **One-pot synthesis of genistein from**

433 **tyrosine by coincubation of genetically engineered *Escherichia coli* and *Saccharomyces***

434 ***cerevisiae* cells. *Appl Microbiol Biotechnol* 2007, **73**:1143-1149.**

435 55. Wu J, Liu P, Fan Y, Bao H, Du G, Zhou J, Chen J: **Multivariate modular metabolic**

436 **engineering of *Escherichia coli* to produce resveratrol from L-tyrosine. *J Biotechnol* 2013,**

437 **167:404-411.**

438 56. Wang S, Zhang S, Xiao A, Rasmussen M, Skidmore C, Zhan J: **Metabolic engineering of**

439 ***Escherichia coli* for the biosynthesis of various phenylpropanoid derivatives. *Metab Eng***

440 **2015, **29**:153-159.**

441 57. Huang Q, Lin Y, Yan Y: **Caffeic acid production enhancement by engineering a**

442 **phenylalanine over-producing *Escherichia coli* strain. *Biotechnol Bioeng* 2013,**

443 **110:3188-3196.**

444 58. Malla S, Koffas MA, Kazlauskas RJ, Kim B-G: **Production of 7-O-methyl aromadendrin, a**

445 **medicinally valuable flavonoid, in *Escherichia coli*. *Appl Environ Microbiol* 2012,**

446 **78:684-694.**

447 59. Leonard E, Yan Y, Fowler ZL, Li Z, Lim C-G, Lim K-H, Koffas MA: **Strain improvement**

448 **of recombinant *Escherichia coli* for efficient production of plant flavonoids. *Mol Pharm***

449 **2008, **5**:257-265.**

450 60. Pandey RP, Parajuli P, Koirala N, Lee JH, Park YI, Sohng JK: **Glucosylation of**

451 **isoflavonoids in engineered *Escherichia coli*. *Mol Cells* 2014, **37**:172.**

452 61. Li J, Li Z, Li C, Gou J, Zhang Y: **Molecular cloning and characterization of an isoflavone**

453 **7-O-glucosyltransferase from *Pueraria lobata*. *Plant Cell Rep* 2014, **33**:1173-1185.**

454 62. Alper H, Miyaoku K, Stephanopoulos G: **Construction of lycopene-overproducing *E. coli***

455 **strains by combining systematic and combinatorial gene knockout targets. *Nat Biotechnol***

456 **2005, **23**:612-616.**

457 63. Survase SA, Saudagar PS, Singhal RS: **Enhanced production of scleroglucan by *Sclerotium***

458 ***rolfsii* MTCC 2156 by use of metabolic precursors. *Bioresour Technol* 2007, **98**:410-415.**

459 64. Chen X-S, Ren X-D, Dong N, Li S, Li F, Zhao F-L, Tang L, Zhang J-H, Mao Z-G: **Culture**

460 **medium containing glucose and glycerol as a mixed carbon source improves**

461 **ϵ -poly-L-lysine production by *Streptomyces* sp. M-Z18. *Bioprocess Biosyst Eng* 2012,**

462 **35:469-475.**

463 65. Da Silva SB, Cantarelli VV, Ayub MAZ: **Production and optimization of poly- γ -glutamic**

464 **acid by *Bacillus subtilis* BL53 isolated from the Amazonian environment. *Bioprocess***

465 *Biosyst Eng* 2014, **37**:469-479.

466

467

468

Figure 1

Figure 2

Prebiotics

2'-Fucosyllactose (2'-FL)

Galacto-oligosaccharides (GOS)

Fructo-oligosaccharides (FOS)

Polysaccharides

Hyaluronic acid

Chondroitin

Scleroglucan polysaccharide

Poly amino acids

Poly-γ-glutamic acid (γ-PGA)

Cyanophycin

Poly-ε-L-lysine (ε-PL)

Graphical Abstract